EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Glycopyrronium 320 μg/ mL in children and adolescents with severe sialorrhoea and neurodisabilities: A randomized, double‐blind, placebo‐controlled trial

Pierre Fayoux iD, Mickael Dinomais iD, Helen Shaw iD, Frédéric Villain iD, Déborah Schwartz, Stéphane Rondeau iD, Guy Letellier iD, Stéphane Auvin iD

Developmental Medicine & Child Neurology · 2024

DOI: 10.1111/dmcn.15841 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Developmental Medicine & Child Neurology, 2024. Verfasst von Pierre Fayoux und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Otolaryngology Head Neck Surgery, Jeanne de Flandre Hospital, Lille, France. Hauptthemen laut MEDLINE: Sialorrhea, Glycopyrrolate, Quality of Life. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Proveca Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate the efficacy, safety, and impact on quality of life (QoL) of an oral formulation of 320 μg/mL glycopyrronium designed for children.

Method

A double‐blind, placebo‐controlled SALIVA (Sialanar plus orAl rehabiLitation against placebo plus oral rehabilitation for chIldren and adolescents with seVere sialorrhoeA and neurodisabilities) trial was conducted. Children (3–17 years) with neurodisabilities and severe sialorrhoea (modified Teachers Drooling Scale ≥6) were randomized to 320 μg/mL glycopyrronium or placebo, in addition to non‐pharmacological standard care.

Results

Of 87 participants, 44 were aged 10 years or under and 43 had cerebral palsy. The primary endpoint, change in total Drooling Impact Scale (DIS) score from baseline to day 84, was significantly greater (improved) with 320 μg/mL glycopyrronium versus placebo (median [quartile 1, quartile 3] –29.5 [−44.5, 0] vs −1 [−16, 5]; p < 0.001), an effect also observed at day 28 (median − 25 vs −2; p < 0.01). Significant reduction in bibs/clothes used per day was seen with glycopyrronium versus placebo at day 84 (median − 2 vs 0; p < 0.01). Glycopyrronium significantly improved DIS items 9 and 10 related to the extent that drooling affects the child's and family's life ( p ≤ 0.03). Adverse events were reported by 77.3% and 69.8% of children with glycopyrronium and placebo respectively; the most common treatment‐related adverse event was constipation (20.5% and 16.3%).

Interpretation

The formulation of 320 μg/mL glycopyrronium significantly improved drooling and reduced its impact on QoL, with good tolerability in children with neurodisabilities. What this paper adds The formulation of 320 μg/mL glycopyrronium significantly improved Drooling Impact Scale score versus placebo at day 84. The formulation reduced the impact of drooling on the child's and family's quality of life. There were no safety or tolerability concerns with this specific formulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SialorrheaGlycopyrrolateQuality of LifeHumansChildDouble-Blind MethodMaleFemaleAdolescentChild, PreschoolMuscarinic AntagonistsCerebral PalsyTreatment OutcomeSeverity of Illness Index

Substanzen

GlycopyrrolateMuscarinic Antagonists

Autor:innen und Institutionen

  • Department of Paediatric Otolaryngology Head Neck Surgery, Jeanne de Flandre Hospital, Lille, France.
  • ULR 2694 - METRICS: Évaluation des technologies de santé et des pratiques médicales, Université de Lille, Lille, France.
  • Department of Physical Medicine and Rehabilitation, CHU Angers-Les Capucins, Angers, France.
  • Proveca Ltd, Manchester, UK.
  • Kappa Santé, Paris, France.
  • Department of Early Medico-Social Action (CAMSP), CHU de Rouen, Rouen, France.

ORCID-Profile: Pierre Fayoux, Mickael Dinomais, Helen Shaw, Frédéric Villain, Stéphane Rondeau, Guy Letellier, Stéphane Auvin

Förderung

  • Proveca Ltd

Zitieren

APA

Fayoux, P., Dinomais, M., Shaw, H., Villain, F., Schwartz, D., Rondeau, S., Letellier, G., & Auvin, S. (2024). Glycopyrronium 320 μg/ mL in children and adolescents with severe sialorrhoea and neurodisabilities: A randomized, double‐blind, placebo‐controlled trial. Developmental Medicine & Child Neurology. https://doi.org/10.1111/dmcn.15841

Vancouver

Fayoux P, Dinomais M, Shaw H, Villain F, Schwartz D, Rondeau S, et al. Glycopyrronium 320 μg/ mL in children and adolescents with severe sialorrhoea and neurodisabilities: A randomized, double‐blind, placebo‐controlled trial. Developmental Medicine & Child Neurology. 2024. doi:10.1111/dmcn.15841

BibTeX
@article{Fayoux2024,
  author = {Fayoux, Pierre and Dinomais, Mickael and Shaw, Helen and Villain, Frédéric and Schwartz, Déborah and Rondeau, Stéphane and Letellier, Guy and Auvin, Stéphane},
  title = {Glycopyrronium 320 μg/ mL in children and adolescents with severe sialorrhoea and neurodisabilities: A randomized, double‐blind, placebo‐controlled trial},
  journal = {Developmental Medicine & Child Neurology},
  year = {2024},
  doi = {10.1111/dmcn.15841}
}
Kostenlos starten →